References
- 1Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122(2):156–63. DOI: 10.1161/CIRCULATIONAHA.109.911818
- 2Boucly A, Gerges C, Savale L, et al. Pulmonary arterial hypertension. Presse Med. 2023;52(3):
104168 . DOI: 10.1016/j.lpm.2023.104168 - 3Humbert M, Guignabert C, Bonnet S, Dorfmüller P, Klinger JR, Nicolls MR, et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J. 2019;53(1):
1801887 . DOI: 10.1183/13993003.01887-2018 - 4Thenappan T, Ormiston ML, Ryan JJ, Archer SL. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ. 2018;360:
j5492 . DOI: 10.1136/bmj.j5492 - 5Bourgeois A, Omura J, Habbout K, Bonnet S, Boucherat O. Pulmonary arterial hypertension: New pathophysiological insights and emerging therapeutic targets. Int J Biochem Cell Biol. 2018;104:9–13. DOI: 10.1016/j.biocel.2018.08.015
- 6Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46(4):903–75. DOI: 10.1183/13993003.01032-2015
- 7Kamen MD. A cupful of luck, a pinch of sagacity. Annu Rev Biochem. 1986;55:1–34. DOI: 10.1146/annurev.bi.55.070186.000245
- 8Demerouti E, Karyofyllis P, Athanassopoulos G, Karatasakis G, Tsiapras D, Manginas A, et al. Pulmonary arterial hypertension associated with interferon-beta treatment for multiple sclerosis. Case report and literature review. Mult Scler Relat Disord. 2019;28:273–5. DOI: 10.1016/j.msard.2019.01.018
- 9Zanatta E, Polito P, Famoso G, Larosa M, De Zorzi E, Scarpieri E, et al. Pulmonary arterial hypertension in connective tissue disorders: Pathophysiology and treatment. Exp Biol Med (Maywood). 2019;244(2):120–31. DOI: 10.1177/1535370218824101
- 10Ha YJ, Lee YJ, Kang EH. Lung Involvements in Rheumatic Diseases: Update on the Epidemiology, Pathogenesis, Clinical Features, and Treatment. Biomed Res Int. 2018;2018:
6930297 . DOI: 10.1155/2018/6930297 - 11Tselios K, Gladman DD, Urowitz MB. Systemic lupus erythematosus and pulmonary arterial hypertension: links, risks, and management strategies. Open Access Rheumatol. 2017;9:1–9. DOI: 10.2147/OARRR.S123549
- 12Orihara Y, Asakura M, Hida N, Kawai M, Sato T, Nishimura K, et al. Effect of Oral Qing-Dai Medication on Pulmonary Arterial Pressure Levels in Patients With Ulcerative Colitis. Circ J. 2020;84(8):1339–45. DOI: 10.1253/circj.CJ-19-1112
- 13Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JSR, Vrapi F, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med. 2009;179(2):151–7. DOI: 10.1164/rccm.200806-953OC
- 14Fuso L, Pitocco D, Antonelli-Incalzi R. Diabetic lung, an underrated complication from restrictive functional pattern to pulmonary hypertension. Diabetes Metab Res Rev. 2019;35(6):
e3159 . DOI: 10.1002/dmrr.3159 - 15Conrad N, Verbeke G, Molenberghs G, Goetschalckx L, Callender T, Cambridge G, et al. Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. Lancet. 2022;400(10354):733–43. DOI: 10.1016/S0140-6736(22)01349-6
- 16Hammer GP, du Prel JB, Blettner M. Avoiding bias in observational studies: part 8 in a series of articles on evaluation of scientific publications. Dtsch Arztebl Int. 2009;106(41):664–8. DOI: 10.3238/arztebl.2009.0664
- 17Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet. 2014;23(R1):R89–98. DOI: 10.1093/hmg/ddu328
- 18Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. 2018;362:
k601 . DOI: 10.1136/bmj.k601 - 19Cuthbertson I, Morrell NW, Caruso P. BMPR2 Mutation and Metabolic Reprogramming in Pulmonary Arterial Hypertension. Circ Res. 2023;132(1):109–126. DOI: 10.1161/CIRCRESAHA.122.321554
- 20Yoshida Y, Uchida K, Kodo K, et al. Genetic and functional analyses of TBX4 reveal novel mechanisms underlying pulmonary arterial hypertension. J Mol Cell Cardiol. 2022;171:105–116. DOI: 10.1016/j.yjmcc.2022.07.002
- 21Thoré P, Girerd B, Jaïs X, et al. Phenotype and outcome of pulmonary arterial hypertension patients carrying a TBX4 mutation. Eur Respir J. 2020;55(5):
1902340 . Published 2020 May 14. DOI: 10.1183/13993003.02340-2019 - 22Wang RR, Yuan TY, Wang JM, Chen YC, Zhao JL, Li MT, et al. Immunity and inflammation in pulmonary arterial hypertension: From pathophysiology mechanisms to treatment perspective. Pharmacol Res. 2022;180:
106238 . DOI: 10.1016/j.phrs.2022.106238 - 23Montani D, Henry J, O’Connell C, Jaïs X, Cottin V, Launay D, et al. Association between Rheumatoid Arthritis and Pulmonary Hypertension: Data from the French Pulmonary Hypertension Registry. Respiration. 2018;95(4):244–50. DOI: 10.1159/000485631
- 24Fayed H, Coghlan JG. Pulmonary Hypertension Associated with Connective Tissue Disease. Semin Respir Crit Care Med. 2019;40(2):173–83. DOI: 10.1055/s-0039-1685214
- 25Jeon CH, Chai JY, Seo YI, Jun JB, Koh EM, Lee SK, et al. Pulmonary hypertension associated with rheumatic diseases: baseline characteristics from the Korean registry. Int J Rheum Dis. 2012;15(5):e80–89. DOI: 10.1111/j.1756-185X.2012.01815.x
- 26Reeves GEM, Collins N, Hayes P, Knapp J, Squance M, Tran H, et al. SAPHIRE: Stress and Pulmonary Hypertension in Rheumatoid Evaluation-A Prevalence Study. Int J Rheumatol. 2016;2016:
4564531 . DOI: 10.1155/2016/4564531 - 27Shariff N, Kumar A, Narang R, Malhotra A, Mukhopadhyaya S, Sharma SK. A study of pulmonary arterial hypertension in patients with rheumatoid arthritis. Int J Cardiol. 2007;115(1):75–6. DOI: 10.1016/j.ijcard.2006.01.013
- 28Udayakumar N, Venkatesan S, Rajendiran C. Pulmonary hypertension in rheumatoid arthritis--relation with the duration of the disease. Int J Cardiol. 2008;127(3):410–2. DOI: 10.1016/j.ijcard.2007.04.084
- 29Nicola PJ, Maradit-Kremers H, Roger VL, Jacobsen SJ, Crowson CS, Ballman KV, et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum. 2005;52(2):412–20. DOI: 10.1002/art.20855
- 30Azpiri-Lopez JR, Galarza-Delgado DA, Colunga-Pedraza IJ, Arvizu-Rivera RI, Cardenas-de la Garza JA, Vera-Pineda R, et al. Echocardiographic evaluation of pulmonary hypertension, right ventricular function, and right ventricular-pulmonary arterial coupling in patients with rheumatoid arthritis. Clin Rheumatol. 2021;40(7):2651–6. DOI: 10.1007/s10067-020-05544-z
- 31Sadeghi S, Granton JT, Akhavan P, Pasarikovski CR, Roos AM, Thenganatt J, et al. Survival in rheumatoid arthritis-associated pulmonary arterial hypertension compared with idiopathic pulmonary arterial hypertension. Respirology. 2015;20(3):481–7. DOI: 10.1111/resp.12464
- 32Naganuma M, Sugimoto S, Suzuki H, Matsuno Y, Araki T, Shimizu H, et al. Adverse events in patients with ulcerative colitis treated with indigo naturalis: a Japanese nationwide survey. J Gastroenterol. 2019;54(10):891–6. DOI: 10.1007/s00535-019-01591-9
- 33Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580–8. DOI: 10.1136/ard.2010.138461
- 34Messina R, Guggino G, Benfante A, Scichilone N. Interstitial Lung Disease in Elderly Rheumatoid Arthritis Patients. Drugs Aging. 2020;37(1):11–8. DOI: 10.1007/s40266-019-00727-z
- 35Hyland RH, Gordon DA, Broder I, Davies GM, Russell ML, Hutcheon MA, et al. A systematic controlled study of pulmonary abnormalities in rheumatoid arthritis. J Rheumatol. 1983;10(3):395–405.
- 36Kim EA, Lee KS, Johkoh T, Kim TS, Suh GY, Kwon OJ, et al. Interstitial lung diseases associated with collagen vascular diseases: radiologic and histopathologic findings. Radiographics. 2002;22 Spec No:S151–165. DOI: 10.1148/radiographics.22.suppl_1.g02oc04s151
- 37Shi H, Zhao Y, Li S, Wu H, Ma D, Wan C. TNF-α and IL-8 levels are positively correlated with hypobaric hypoxic pulmonary hypertension and pulmonary vascular remodeling in rats. Open Life Sci. 2023;18(1):
20220650 . Published 2023 Jul 27. DOI: 10.1515/biol-2022-0650 - 38Kumar M, Murugesan S, Ibrahim N, Elawad M, Al Khodor S. Predictive biomarkers for anti-TNF alpha therapy in IBD patients. J Transl Med. 2024;22(1):
284 . Published 2024 Mar 16. DOI: 10.1186/s12967-024-05058-1 - 39Ungprasert P, Srivali N, Spanuchart I, Thongprayoon C, Knight EL. Risk of venous thromboembolism in patients with rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol. 2014;33(3):297–304. DOI: 10.1007/s10067-014-2492-7
- 40Dawson JK, Goodson NG, Graham DR, Lynch MP. Raised pulmonary artery pressures measured with Doppler echocardiography in rheumatoid arthritis patients. Rheumatology (Oxford). 2000;39(12):1320–5. DOI: 10.1093/rheumatology/39.12.1320
- 41Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum. 2014;43(5):613–26. DOI: 10.1016/j.semarthrit.2013.09.005
- 42Cansu DÜ, Korkmaz C. Pulmonary hypertension in connective tissue diseases: epidemiology, pathogenesis, and treatment. Clin Rheumatol. 2023;42(10):2601–10. DOI: 10.1007/s10067-022-06446-y
- 43Iudici M, Codullo V, Giuggioli D, Riccieri V, Cuomo G, Breda S, et al. Pulmonary hypertension in systemic sclerosis: prevalence, incidence and predictive factors in a large multicentric Italian cohort. Clin Exp Rheumatol. 2013;31(2 Suppl 76):31–6.
- 44Thakkar V, Lau EMT. Connective tissue disease-related pulmonary arterial hypertension. Best Pract Res Clin Rheumatol. 2016;30(1):22–38. DOI: 10.1016/j.berh.2016.03.004
- 45Attanasio U, Cuomo A, Pirozzi F, Loffredo S, Abete P, Petretta M, et al. Pulmonary Hypertension Phenotypes in Systemic Sclerosis: The Right Diagnosis for the Right Treatment. Int J Mol Sci. 2020;21(12):
4430 . DOI: 10.3390/ijms21124430 - 46Sangani RA, Lui JK, Gillmeyer KR, Trojanowski MA, Bujor AM, LaValley MP, et al. Clinical characteristics and outcomes in pulmonary manifestations of systemic sclerosis: Contribution from pulmonary hypertension and interstitial lung disease severity. Pulm Circ. 2022;12(4):
e12117 . DOI: 10.1002/pul2.12117 - 47Demerouti E, Karyofyllis P, Athanassopoulos G, Karatasakis G, Tsiapras D, Manginas A, et al. Pulmonary arterial hypertension associated with interferon-beta treatment for multiple sclerosis. Case report and literature review. Mult Scler Relat Disord. 2019;28:273–5. DOI: 10.1016/j.msard.2019.01.018
- 48Ribeiro Baptista B, Petitpain N, Gomez E, Yelehé-Okouma M, Valentin S, Guillaumot A, et al. Pulmonary arterial hypertension in patient treated for multiple sclerosis with 4-aminopyridine. Fundam Clin Pharmacol. 2019;33(1):127–9. DOI: 10.1111/fcp.12396
- 49Fuso L, Pitocco D, Antonelli-Incalzi R. Diabetic lung, an underrated complication from restrictive functional pattern to pulmonary hypertension. Diabetes Metab Res Rev. 2019;35(6):
e3159 . DOI: 10.1002/dmrr.3159 - 50Weynand B, Jonckheere A, Frans A, Rahier J. Diabetes mellitus induces a thickening of the pulmonary basal lamina. Respiration. 1999;66(1):14–9. DOI: 10.1159/000029331
- 51Chen J, Wang Q, Li R, Li Z, Jiang Q, Yan F, et al. The role of sirtuins in the regulatin of oxidative stress during the progress and therapy of type 2 diabetes mellitus. Life Sci. 2023;333:
122187 . DOI: 10.1016/j.lfs.2023.122187 - 52Lopez-Lopez JG, Moral-Sanz J, Frazziano G, Gomez-Villalobos MJ, Moreno L, Menendez C, et al. Type 1 diabetes-induced hyper-responsiveness to 5-hydroxytryptamine in rat pulmonary arteries via oxidative stress and induction of cyclooxygenase-2. J Pharmacol Exp Ther. 2011;338(1):400–7. DOI: 10.1124/jpet.111.179515
- 53Hua H, Goldberg HJ, Fantus IG, Whiteside CI. High glucose-enhanced mesangial cell extracellular signal-regulated protein kinase activation and alpha1(IV) collagen expression in response to endothelin-1: role of specific protein kinase C isozymes. Diabetes. 2001;50(10):2376–83. DOI: 10.2337/diabetes.50.10.2376
- 54Arnold N, Koppula PR, Gul R, Luck C, Pulakat L. Regulation of cardiac expression of the diabetic marker microRNA miR-29. PLoS One. 2014;9(7):
e103284 . DOI: 10.1371/journal.pone.0103284 - 55Moral-Sanz J, Lopez-Lopez JG, Menendez C, Moreno E, Barreira B, Morales-Cano D, et al. Different patterns of pulmonary vascular disease induced by type 1 diabetes and moderate hypoxia in rats. Exp Physiol. 2012;97(5):676–86. DOI: 10.1113/expphysiol.2011.062257
- 56Liu D, Yan Y, Chen JW, et al. Hypermethylation of BMPR2 Promoter Occurs in Patients with Heritable Pulmonary Arterial Hypertension and Inhibits BMPR2 Expression. Am J Respir Crit Care Med. 2017;196(7):925–928. DOI: 10.1164/rccm.201611-2273LE
- 57Bisserier M, Mathiyalagan P, Zhang S, et al. Regulation of the Methylation and Expression Levels of the BMPR2 Gene by SIN3a as a Novel Therapeutic Mechanism in Pulmonary Arterial Hypertension. Circulation. 2021;144(1):52–73. DOI: 10.1161/CIRCULATIONAHA.120.047978
- 58Chelladurai P, Dabral S, Basineni SR, et al. Isoform-specific characterization of class I histone deacetylases and their therapeutic modulation in pulmonary hypertension. Sci Rep. 2020;10(1):
12864 . Published 2020 Jul 30. DOI: 10.1038/s41598-020-69737-x - 59Wang Y, Huang XX, Leng D, Li JF, Liang Y, Jiang T. Effect of EZH2 on pulmonary artery smooth muscle cell migration in pulmonary hypertension. Mol Med Rep. 2021;23(2):
129 . DOI: 10.3892/mmr.2020.11768 - 60Li XC, Zhu XY, Wang YY, et al. Canagliflozin alleviates pulmonary hypertension by activating PPARγ and inhibiting its S225 phosphorylation. Acta Pharmacol Sin. 2024;45(9):1861–1878. DOI: 10.1038/s41401-024-01286-9